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use in the community (spillover effect). CONCLUSIONS: Evergreening drugs suc-
cessfully compete with generics, offsetting cost containment strategies including
generic medication substitution or a hospital RDF, particularly so if hospitals in-
clude evergreening or brand drugs on their RDF. For effectiveness, prescriptions
should be coordinated at the state level rather than from a payer perspective, or
hospitals should implement strategies to systematically switch patients to generic
drugs at discharge.
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OBJECTIVES: In 2006 a law for the economical use of medications was introduced
into the Hungarian legislation. This law – among others – facilitated the foundation
of new pharmacies. The aim of our study is to analyse the effect of that legislation
on the number of pharmacies.METHODS:Data were derived from the pharmaceu-
tical database of the Hungarian Health Insurance Fund Administration (OEP), the
only health care financing agency in Hungary. We analysed the 5 years period
between 2006-2010. The number of pharmacies were analysed according to the
number of population of different settlements. RESULTS: The number of commu-
nity pharmacies increased from 2030 (2006) to 2576 (2010) by 546 pieces (26.9 %).
The number of pharmacies showed a different pattern according to the size of
population of settlements. In villages with a population of 0-449, 500-999 and 1000-
1999, the number of pharmacies decreased (3 pieces / 3.6 %; 18 pieces / 20.0 %; 23
pieces / 10.6 % respectively). In cities with a population between 2000-4999 we
found a slight increase in the number of pharmacies (11 pieces / 3.0 %). In bigger
towns there was a clear increase in the number of pharmacies: 5000-9999 popula-
tion 53 pieces / 29.0 %; 10000-49999 194 pieces / 37.1 %; 50000-99999 population 129
pieces / 33.0 % and over the population of 100000: 158 pieces / 42.9 %.
CONCLUSIONS: After the introduction of the new law for the economical use of
medications in 2006, the number of pharmacies significantly changed in Hungary.
However, this change in the number of pharmacies was inequal according to the
size of the population: in villages with a population lower than 2000 people there
was a decrease, while in cities with bigger population the number of pharmacies
significantly increased.
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OBJECTIVES: During 2009-2012 major health care reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the United
States, AMNOG in Germany, HSPT in France, KVG in Switzerland, Ustawa Refun-
dacyjna in Poland and NHS proposed reform in the UK. These reforms have major
implications on pricing, market access and HEOR strategy for drug and device
products. METHODS: To understand the implications of these trends, we analyzed
2009-2012 reform bills and proposed changes worldwide. Additionally, we inter-
viewed public and private payers, key opinion leaders and payer-influencers to
understand implications of these reforms on drug and device manufacturers.
Stakeholders ranked various data collection methods on a scale of 1-10 (1-least
important and 10-most important). RESULTS: The global health care landscape is
expected to undergo significant change during 2012-2016. In the United States,
government will play increased role as a single payer, especially with?Medicare,
Medicaid and CHIP programs? which will cover 114 million Americans, at a cost of
$784 billion. In Germany, AMNOG bill marked the end of free drug pricing and
would lead to increased insurance premiums (now 15.5% of wages). In the UK, NHS
has proposed to replace PCTs with 500-1000 GP-led consortia and use value-based
pricing for expensive drugs and devices. Randomized controlled trial, budget im-
pact model and systematic reviews —ranked highest (7.5-9.1) among payers. Over-
all, payers view that in the future, health economic assessments would play critical
role in pricing, coverage and reimbursement of branded products. CONCLUSIONS:
This analysis shows that global health care landscape is expected to undergo sig-
nificant change during 2012-2016. Discussions with payers, KOLs and payer-influ-
encers highlights increased importance of HEOR data in the future.
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OBJECTIVES: To review the impact orphan drug (OD) legislation has had on inno-
vation and pricing of therapeutic products for rare diseases in the US, EU, and
Japan. METHODS: A systematic literature review was conducted, seeking English-
language studies published after the enactment of initial OD legislation in 1983.
EMBASE, Medline, and Business Source Complete were searched and results
screened for studies specifically assessing the impact of industry-focused policy
interventions using 1) measurable innovation- and pricing-related outcomes, and
2) specifying appropriate comparators. In addition to being abstracted for informa-
tion on research setting, counterfactuals, outcomes, and findings, the methodolog-
ical quality of included studies was evaluated with an adapted tool. RESULTS:
Twenty unique studies met the inclusion criteria: 14 discussing innovation out-
comes and 7 discussing pricing outcomes. Increasingly strong study designs have
been used to validate that that OD legislation has increased cross-market approv-
als and suggest the increasing role of small biotechnology companies. Select re-
search also shows a positive relationship between disease prevalence and the
likelihood of indicated ODs and is bolstered by well-controlled regression-continu-
ity studies showing sustained innovation in higher prevalence OD markets. How-
ever, some concerns are raised regarding innovation in low prevalence conditions
and conditions just above OD thresholds. Pricing studies were almost exclusively
focused on the EU. A multiple-regression analysis demonstrated that merely hav-
ing an OD designation leads to a higher price, with 4 weaker studies suggesting an
inverse relationship between rare disease prevalence and acquisition price.
CONCLUSIONS: Despite an abundance of opinion and case study pieces in OD
literature, specific studies of high internal validity exist, as do defined and usable
comparator group classifications. The reviewed studies ought to serve as valuable
information for policymakers considering policy extensions for ultra-orphans, in-
ternational markets, or other niche therapeutic areas, as well as demonstration of
best-practices in designing well-controlled studies evaluating biopharmaceutical
policies.
PHP16
GENERIC DRUG MARKET ACCESS IN JAPAN
Yoshida E1, Toumi M2
1Creativ-Ceutical Ltd, London, UK, 2University Claude Bernard Lyon 1, Lyon, France
The Japanese generic drug market is not well developed. The generic volume share
is 20% of the total market vs. 74% and 64% in the USA and UK. The slow uptake of
generics is often explained by the “Brand Lover” profile of Japan. No formal review
of drug policy has been undertaken to understand the slow uptake of generics.
OBJECTIVES: To review the current Japanese drug policy regarding generic drugs
and to appreciate the incentive and disincentive to use generic. METHODS: We
reviewed the current Japanese generic drug policy enacted by the Ministry of
Health, Labour and Welfare (MHLW), and the Japanese Generic Medicines Associ-
ation’s website. RESULTS: Major policies to enhance generic uptake were issued in
2002, 2006 and 2010. They required that prescriptions specify if substitution gener-
ics are acceptable, and provide some modest financial incentives for pharmacies
and hospitals to substitute only with the patient’s agreement. In 2012, INN pre-
scription is encouraged but not requested. The recent introduction of Japanese DRG
hospital funding, and the 2011 Japan-India Economic Partnership Agreement,
which opened the Japanese market to Indian generic drug manufacturers, are ex-
pected to boost the generic market. However, small pricing gaps between generic
and branded drugs, the lack of mandatory substitution and INN prescription, little
price discounting and little education towards the public might explain the slow
uptake of generics in Japan, relative to the West. CONCLUSIONS: Although the
“Brand Lover” assumption is candidly used to explain the lack of traction by generic
drugs, this review finds the lack of policy incentives to boost generic adoption,
better explain current levels of generics penetration. Shall the authorities be will-
ing to encourage generic uptake more effective policy incentive are needed.
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OBJECTIVES: Cost effectiveness analyses play a critical role in determining cover-
age of novel drugs and devices. Increasingly, payers are demanding subgroup anal-
yses to determine indications which would be covered by the national health sys-
tem or insurance agency. METHODS: To understand and review trends in use of
subgroup cost effectiveness analysis, we analyzed NICE HTAs for products ap-
proved in 2011-2012. Manufacturer submissions for CEA were compared to final
review and decision by HTA agency. Analogs were identified and case studies were
developed to further understand the use of subgroup analyses and cost effective-
ness models. RESULTS: Decisions made by NICE in 2011-2012 show increasing
trends towards the use of subgroup analysis for determining indications for cov-
erage by national payer bodies. During 2011-2012, 80% of the assessments included
subgroup analyses. Approximately half of them included cost effectiveness anal-
yses for various subgroups. Interestingly, the ICER values estimated by NICE for the
same subgroups showed a large variation (1X-3X fold difference) compared to ICER
values estimated by manufacturers. Selected case studies highlighted that for sev-
eral products NICE is recommending treatments only for subgroups whose ICER
values are within the cost effectiveness threshold. CONCLUSIONS: New products
need robust broader population and subgroup analyses for insurance coverage.
PHP18
THE EFFECT OF LAW FOR ECONOMICAL USE OF MEDICATIONS 2006 ON THE
CATCHMENT POPULATION OF COMMUNITY PHARMACIES BETWEEN 2007-2010
Boncz I1, Donka-Verebes É2, Oberfrank F3
1University of Pécs, Pécs, Hungary, 2Integra Consulting zRt., Budapest, Hungary, 3Institute of
Experimental Medicine (IEM)., Budapest, Hungary
OBJECTIVES: In 2006 a law for the economical use of medications was introduced
into the Hungarian legislation. This law – among others – facilitated the foundation
of new pharmacies. The aim of our study is to analyse the effect of that legislation
on the catchment population of community pharmacies. METHODS: Data were
derived from the pharmaceutical database of the Hungarian Health Insurance
Fund Administration (OEP), the only health care financing agency in Hungary. We
analysed the 5 years period between 2006-2010. The main indicator of our analyses
is the average population of one pharmacy (catchment population) in the counties
of Hungary. RESULTS: The average catchment population of a pharmacy was 4933
inhabitants (( 592, standard deviation, SD) in 2006, while in 2010 it decreased to
3.888 ( 450) inhabitants per pharmacy. We found the largest catchment popula-
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